{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-032185","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.630900+00:00","generated_at":"2026-06-10T19:37:57.286044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Champions Oncology Q1 revenue $12.6M, down 9%; operating loss widens to $2.6M","bullets":["Revenue $12.6M vs $13.7M YoY (-8.6%); gross margin 38.8% vs 48.7%.","Operating loss $2.6M vs loss of $284K; adjusted EBITDA loss $1.7M vs positive $450K.","Cash $5.0M, no debt; net cash used in ops $4.0M for the quarter.","CEO cites biotech downturn; bookings improving, expects revenue growth in H2.","Drug discovery subsidiary Corellia AI progressing; company seeking capital to accelerate programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-032185","json":"https://secwatch.observer/filing/0001628280-23-032185.json","markdown":"https://secwatch.observer/filing/0001628280-23-032185.md","text":"https://secwatch.observer/filing/0001628280-23-032185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/csbr-20230913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:37:57.286044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0f219246c52dd0108ca99e0346e7d35770d1ca7","claim":"CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.","evidence_excerpt":"Total revenue for the first quarter of fiscal 2024 was $12.6 million compared to $13.7 million for the same period last year, a decrease of 8.6%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal 2024 ended July 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a0f219246c52dd0108ca99e0346e7d35770d1ca7","claim":"CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.","evidence_excerpt":"For the first quarter of fiscal 2024, Champions reported a loss from operations of $2.6 million , including $423,000 in stock-based compensation and $445,000 in depreciation and amortization expenses, compared to a loss from operations of $284,000 , inclusive of $206,000 in stock-based compensation and $528,000 in depreciation and amortization expenses, in the first quarter of fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal 2024 ended July 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a0f219246c52dd0108ca99e0346e7d35770d1ca7","claim":"CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.","evidence_excerpt":"Excluding stock-based compensation, depreciation and amortization expenses, Champions reported an adjusted EBITDA loss of $1.7 million for the first quarter of fiscal 2024 compared to adjusted EBITDA of $450,000 in the first quarter of fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828023032185/0001628280-23-032185-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal 2024 ended July 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}